MedTrace Logo

Clinical Trial to Investigate Efficacy of LAS41004 in Psoriasis

NCT01283698 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2015-05-29

No results posted yet for this study

Summary

The aim of the study is to intra-individually compare the dose-related efficacy of LAS41004 in a Psoriasis Plaque Test (PPT)

Conditions

Interventions

DRUG

Experimental: LAS 41004 dosage 1

dosage 1, once daily

DRUG

Experimental: LAS 41004 dosage 2

LAS 41004 dosage 2, once daily

DRUG

Experimental: LAS 41004 dosage 3

dosage 3, once daily

DRUG

Placebo Comparator: placebo

once daily

DRUG

Reference

Active Comparator,once daily

Sponsors & Collaborators

  • Almirall, S.A.

    lead INDUSTRY

Principal Investigators

  • Christoph Willers, MD, MBA · Almirall Hermal GmbH

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2011-03-31
Completion
2011-03-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01283698 on ClinicalTrials.gov